摘要
目的:探讨伊马替尼与干扰素联合化疗治疗慢性粒细胞白血病(CM L)的疗效。方法:2004年6月—2009年7月新诊断的58例Ph染色体阳性CM L慢性期患者,随机分为伊马替尼组和干扰素联合化疗组,比较两组临床疗效。结果:两组总有效率差异无统计学意义(P>0.05);伊马替尼组完全血液学缓解率,完全细胞遗传学缓解率、完全分子学效应率、5年总生存率均明显高于干扰素联合化疗组(P<0.05)。结论:伊马替尼和干扰素联合化疗都可作为CM L慢性期的有效治疗方法,应依据不同情况实施个体化治疗。
Objective：To investigate the efficacy of imatinib and interferon combined with chemotherapy for chronic myeloid leukemia （CML）. Methods：From June 2004 to July 2009,58 patients newly diagnosed CML in chronic phase with philadelphia chromosome positive wererandomly divided into two groups,imatinib group and interferon- chemotherapy group. The clinical effects were compared between the two groups. Results ：The total effective rate of two groups was not statistically different （P〉0.05）. The complete hematologic remission rate,complete cytogenetic remission rate ,complete molecular effect rate and 5-year survival rate were higher in the imatinib group than in the in- terferon-chemotherapy group（P〈0. 05）. Conclusion： Both imatinib and interferon-chemotherapy are effective treat ments for CML in chronic phase, Individual treatment scheme should be designed for patients depend on the situation.
出处
《临床医药实践》
2012年第3期171-173,共3页
Proceeding of Clinical Medicine
